Ganglioside Sodium Injection 20 mg, 6 ampoules/2 ml: profile, composition and research

Reference page for Ganglioside Sodium Injection 20 mg, 6 ampoules/2 ml. Active substance: Моносиалотетрагексозилганглиозид натрия (GM1) / Monosialotetrahexosylganglioside sodium (GM1).

Key facts

What ganglioside GM1 is

Gangliosides are fat-like molecules built into the outer membrane of cells. They are especially abundant in the nervous system, where they take part in signal recognition, receptor behaviour and contact between cells. GM1 is a monosialoganglioside and one of the commonest forms found in the membranes of neurons.

The medicine is the sodium salt of monosialotetrahexosylganglioside. The active substance is obtained from porcine brain tissue, purified and turned into a sterile solution for injection. Each ampoule holds 20 mg of the substance in 2 ml, and a pack contains six ampoules.

It comes as a ready-made solution in ampoules and is given parenterally. That sets GM1 apart from oral neurotrophic products: the substance reaches the bloodstream without passing through the digestive tract.

How GM1 acts on nerve cells

Embedded in the neuronal membrane

GM1 is not a signalling molecule in the usual sense. Its role lies in the physical properties of the membrane: it forms dense patches, so-called lipid rafts, where receptors and ion channels gather. The integrity of these patches shapes how signals travel into the cell.

Supporting neurotrophic signalling

Through membrane complexes GM1 influences how sensitive neurons are to growth factors, the proteins that sustain the survival and growth of nerve cells. In experimental models adding the ganglioside strengthened that signalling and reduced cell death after injury.

Limiting secondary damage

After ischaemia or trauma part of the nerve tissue is harmed not at once but over the following hours, through inflammation, glutamate build-up and oxidative stress. In animal studies GM1 acted on these secondary processes, including autophagy and the work of certain intracellular proteins.

Approved areas of use

The product information lists acute and chronic disorders of the central and peripheral nervous system. Among them are ischaemic and haemorrhagic stroke, injuries to the brain and spinal cord, the aftermath of surgery on the nervous system, and neuroinfections.

Diabetic and toxic neuropathy, multiple sclerosis and other demyelinating conditions also appear, along with neurodegenerative states such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. The medicine is usually regarded as part of complex therapy rather than a stand-alone option.

The decision to prescribe, the route of administration and the length of the course belong to a physician. Using the solution on one's own is not acceptable: this concerns severe neurological disease and parenteral administration.

What the research shows

There is a fair amount of published work on GM1 in stroke, but the strength of the evidence varies. A review in Cell Transplantation (2019) sets out the mechanisms in ischaemic stroke and states plainly that part of the findings come from animal models.

Another paper, in Frontiers in Neurology (2019), treats gangliosides as a direction in neurodegenerative disease and stresses that the clinical evidence remains limited and inconsistent.

Some experimental studies, for instance in PLoS One (2016), link the protective effect of GM1 in stroke models to the inhibition of autophagy. Animal findings, however, cannot be carried over to people directly, so conclusions about benefit for patients stay cautious.

Published research

Primary sources, verified against PubMed:

• Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review., PubMed 30666888 (Cell Transplant, 2019).
• Gangliosides: Treatment Avenues in Neurodegenerative Disease., PubMed 31447771 (Front Neurol, 2019).
• Protection against Experimental Stroke by Ganglioside GM1 Is Associated with the Inhibition of Autophagy., PubMed 26751695 (PLoS One, 2016).
• The Possible Damaged Mechanism and the Preventive Effect of Monosialotetrahexosylganglioside in a Rat Model of Cerebral Ischemia-Reperfusion Injury., PubMed 25934141 (J Stroke Cerebrovasc Dis, 2015).

Listed for reference. Publication of a study is not a claim about this particular product.

Precautions

• This is a prescription medicine. Prescribing, the route of administration and monitoring belong to a physician.
• The solution is given parenterally only, in a setting where reactions to the injection can be observed.
• Allergic reactions are possible: swelling, difficulty breathing, rash, itching. Such symptoms must be reported to a doctor at once.
• Reported unwanted effects include headache, dizziness and reactions at the injection site.
• Safety data in pregnancy and breastfeeding are limited. The decision belongs to a physician.
• The product is made from biological material, so tell your doctor about intolerance to any of its components and about other medicines you take.

Frequently asked